CTSC and bronchiectasis: Along with this concept of bronchiectasis as an inflammatory disease, the therapeutic landscape is evolving: brensocatib, a selective oral DPP-1 inhibitor, has shown promise in reducing airway neutrophilic inflammation by inhibiting neutrophil serine protease activation [32].